Literature DB >> 26602266

Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003-2011.

Altynay Shigayeva1, Wallis Rudnick2, Karen Green1, Gregory Tyrrell3, Walter H B Demczuk4, Wayne L Gold5, Jonathan Gubbay6, Frances Jamieson6, Agron Plevneshi1, Sylvia Pong-Porter1, Susan Richardson7, Allison McGeer8.   

Abstract

BACKGROUND: Pneumococcal disease burden is difficult to quantify due to limited data regarding non-bacteremic disease. We assessed serotype-specific differences in pneumococcal disease presentations in adults in Toronto, Canada.
METHODS: From 2003 to 2011, population-based surveillance for invasive pneumococcal disease was conducted and respiratory pneumococcal isolates collected in Metropolitan Toronto/Peel Region, Canada. Episodes of care were classified into disease categories.
RESULTS: Of 3105 eligible cases of IPD, 2060 cases were bacteremic pneumonia, and 1045 bacteremia without pneumonia. Of 2751 eligible respiratory cases, 1542 (56.0%) were non-bacteremic pneumonia (NBPP), 467 (17.0%) were other acute respiratory infection (oARI), and 742 (27.0%) were isolates representing colonization. Serotypes 3 (11.3%), 19A (8.4%) and 22F (6.2%) were the most common; serotypes 1,5, and 8 were rare. Serotypes 4, 14, 7F, 9V, 12F, 14, 19A and 6C were over-represented in bacteremic disease, and serotypes 3, 6A, 11A, 19F, 23A, 23F, 35B, 35F were more common in NBPP. The proportion of cases due to PCV7 serotypes declined from 48.7% to 8.7% in bacteremic pneumonia, from 35.3% to 10.9% in NBPP, from 34.2% to 7.5% in oARI, and from 38.7% to 12.2% in colonizing isolates. In 2010-2011, PCV13 serotypes accounted for 62.6% of isolates associated with bacteremic pneumonia, 42.0% of bacteremia without pneumonia, 41.1% of NBPP, 25.7% of oARI, and 32.9% of colonizing isolates.
CONCLUSIONS: Serotype distributions differ significantly in different presentations of pneumococcal disease. Herd protection due to PCV7 has changed serotype distribution, but PCV13 serotypes remain important in all categories of disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Invasive pneumococcal disease; Pneumococcal vaccine; Pneumonia; Serotype

Mesh:

Year:  2015        PMID: 26602266     DOI: 10.1016/j.vaccine.2015.11.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population-based study.

Authors:  Shalini Desai; Michelle E Policarpio; Kenney Wong; Jonathan Gubbay; Jill Fediurek; Shelley Deeks
Journal:  CMAJ Open       Date:  2016-09-29

2.  Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study.

Authors:  Angela Domínguez; Núria Soldevila; Diana Toledo; Pere Godoy; Núria Torner; Luis Force; Jesús Castilla; José María Mayoral; Sonia Tamames; Vicente Martín; Mikel Egurrola; Francisco Sanz; Jenaro Astray
Journal:  Hum Vaccin Immunother       Date:  2016-04-11       Impact factor: 3.452

3.  Limited impact of pneumococcal vaccines on invasive pneumococcal disease in Nunavik (Quebec).

Authors:  Jean-Baptiste LeMeur; Brigitte Lefebvre; Jean-François Proulx; Philippe De Wals
Journal:  Can J Public Health       Date:  2018-10-19

4.  Serotypes and antibiotic susceptibility of Streptococcus pneumoniae isolated from hospitalized patients with community-acquired pneumonia in Italy.

Authors:  Marta Di Pasquale; Stefano Aliberti; Chara Azzari; Maria Moriondo; Francesco Nieddu; Francesco Blasi; Marco Mantero
Journal:  SAGE Open Med       Date:  2017-07-16

5.  Emergence of Carbapenemase-Producing Enterobacteriaceae, South-Central Ontario, Canada1.

Authors:  Philipp P Kohler; Roberto G Melano; Samir N Patel; Shumona Shafinaz; Amna Faheem; Brenda L Coleman; Karen Green; Irene Armstrong; Huda Almohri; Sergio Borgia; Emily Borgundvaag; Jennie Johnstone; Kevin Katz; Freda Lam; Matthew P Muller; Jeff Powis; Susan M Poutanen; David Richardson; Anu Rebbapragada; Alicia Sarabia; Andrew Simor; Allison McGeer
Journal:  Emerg Infect Dis       Date:  2018-09       Impact factor: 6.883

6.  Role of Streptococcus pneumoniae infection in chronic obstructive pulmonary disease patients in Italy.

Authors:  Marco Mantero; Stefano Aliberti; Chiara Azzari; Maria Moriondo; Francesco Nieddu; Francesco Blasi; Marta Di Pasquale
Journal:  Ther Adv Respir Dis       Date:  2017-08-31       Impact factor: 4.031

7.  The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.

Authors:  Shinthuja Wijayasri; Kelty Hillier; Gillian H Lim; Tara M Harris; Sarah E Wilson; Shelley L Deeks
Journal:  PLoS One       Date:  2019-12-13       Impact factor: 3.240

8.  Factors Associated With Severe Nonmeningitis Invasive Pneumococcal Disease in Adults in France.

Authors:  Kostas Danis; Emmanuelle Varon; Agnès Lepoutre; Cécile Janssen; Emmanuel Forestier; Olivier Epaulard; Yohan N'guyen; Anaïs Labrunie; Philippe Lanotte; Alain Gravet; Isabelle Pelloux; Pascal Chavanet; Daniel Levy-Bruhl; Marie-Cecile Ploy; Jacques Gaillat
Journal:  Open Forum Infect Dis       Date:  2019-11-30       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.